I’m a relatively severe, lifelong insomniac. Over the last year, my deep dive into sleep physiology and pharmacology has led me to a fascinating—yet frustratingly unavailable—compound: gaboxadol (a.k.a. THIP).

After reading some of the clinical literature and Hamilton Morris’s excellent article on the drug (the Wiki article on it is also very well done), I am convinced that gaboxadol represents a massive missed opportunity in sleep medicine. For those of us interested, it is uniquely superior to Z-drugs, benzodiazepines, GHB, and other GABAergics in terms of safety, and somewhat superior to orexin antagonists in terms of efficacy and impact sleep architecture—specifically its robust enhancement of slow-wave sleep (SWS).

The Mechanism: Extrasynaptic Tonic Inhibition

Unlike traditional benzodiazepines and Z-drugs, which act as positive allosteric modulators (PAMs) at synaptic GABA_A receptors to facilitate phasic inhibition (meaning they directly cause an immediate and large influx of chloride into the neuron, reducing its ability to fire action potentials), gaboxadol is a direct orthosteric agonist. It's selective for extrasynaptic δ-subunit-containing GABA_A receptors (specifically the α4β3δ subtype).

These receptors mediate tonic inhibitory conductance. Because they are highly expressed in arousal- and wakefulness-promoting regions like the thalamus, agonizing them mimics a much more physiological onset of sleep. Also, because α4β3δ receptors (where THIP is most active) are positively modulated by histamine, it's possible that agonizing them might create a homeostatic braking effect on the histaminergic tuberomammillary nucleus (this is just a hypothesis of mine, so take with a grain of salt).

Superiority Over Z-Drugs and GHB (Safety & Architecture)

Z-drugs (zolpidem, eszopiclone, etc.) are often sought out for severe insomnia, and other novel GABAergics like GHB and phenibut have their fans in some circles, but they come with profound downsides that gaboxadol avoids.

• Vs. Z-Drugs: Z-drugs primarily bind to α1-containing GABA_A receptors (except zopiclone, which is more promiscuous for other subunits). While they reliably reduce sleep onset latency, they generally suppress or alter deep sleep (N3/SWS). Furthermore, they carry well-documented risks of tolerance, dependence, and parasomnias. Gaboxadol on the other hand enhances N3 sleep, preserves REM, and phase III trials demonstrated virtually no significant tolerance, withdrawal/rebound insomnia (more on these later), or parasomnias. The main side effect noted is hallucinations, which typically manifest at higher-than-therapeutic doses, but I suspect not everyone will view that as an "adverse" effect.
• Vs. GHB: People mention GHB for reliably inducing SWS via GABA_B and GHB receptor agonism. However, it has a notoriously steep dose-response curve and severe and rapid tolerance/withdrawal, causes respiratory depression and dangerous interactions, and causes dopaminergic rebound wakefulness as it clears, waking the user abruptly in the middle of the night and creating a highly fragmented, unnatural polysomnogram. Some people deny the tachyphylaxis, but Reddit it replete with horror stories of GHB withdrawal (and other GABA_B agonists like phenibut). Gaboxadol provides the SWS benefits of GHB but with a vastly superior therapeutic index, rebound effects, and far fewer practical dangers.
• Note: It also lacks the potential neurotoxic risks of α2δ calcium channel inhibitors (like gabapentin/pregabalin and to some extent phenibut), which are sometimes used off-label for SWS enhancement but are known to directly and potently inhibit synaptogenesis.

Superiority Over DORAs/2-SORAs (Efficacy & SWS)

I have a lot of respect for Dual Orexin Receptor Antagonists (DORAs like daridorexant, lemborexant, and the up-and-coming vornorexant) and selective 2-SORAs (seltorexant). They have excellent safety profiles and act as great sleep aids for mild-to-moderate cases, representing the best currently available hypnotics in medicine. They preserve or modestly enhance sleep quality, do not exhibit tolerance (more on this later), and are pretty much devoid of real side effects. I just wish they were more powerful. They have a somewhat low ceiling effect compared to the GABAergics and even antihistamines, and they often lack the punchiness to knock you out.

While ORAs are a clear improvement over Z-drugs because they do not actively suppress SWS, they are primarily known for increasing REM. Some EEG studies show a very slight increase in delta power (deep sleep), while others don't, but I think it's fair to say they don't actively drive deep sleep.

N3/SWS is arguably the most critical sleep stage for neurological health. It mediates glymphatic system clearance, synaptic pruning, memory consolidation, and metabolic restoration (insulin sensitivity, exercise recovery, etc.). You can actually completely abolish your REM sleep with an MAOI and be more or less fine, but a lack of deep sleep would be devastating. If you're wondering how a GABAergic sedative can be considered a "nootropic," then you don't understand how important good sleep is for brain and overall health. In fact, phase III trials showed gaboxadol actually improved daytime functioning scores over placebo.

No Tolerance, You Say?

On tolerance, it's hard to say confidently that it does not cause any tolerance, but I think the evidence shows it is clearly a category difference compared to Z-drugs. My guess is this is because the extrasynaptic receptors on which gaboxadol acts are constantly bathed in endogenous GABA, acting as tonic sensors for GABA levels. Synaptic GABA_A receptors on the other hand are designed to detect massive, extremely short-lived surges in GABA in the synaptic cleft, and are potentially more easily desensitized or internalized when overactivated. There's also the fact that benzodiazepines are positive allosteric modulators*,* meaning they bind to a different part of the receptor compared to GABA and then increase the sensitivity of the receptor to endogenous GABA. This process is can become uncoupled, which is another avenue for benzodiazepine tolerance. The expression the different subunits containing benzodiazepine binding sites can also change over time with prolonged benzodiazepine use, but I digress.

Ultimately I think any GABAergic and most psych drugs will be subject to some tolerance, but like I said, it's a category difference between different classes, not just a difference of degree. Studies also generally show that orexin antagonists are not disposed to tolerance, and while there may be some nuance to that, they are clearly suitable for continual long-term use. Gaboxadol might be similar.

The Merck Mystery & Market Absence

Gaboxadol is remarkably well-studied in large-scale human RCTs (especially among the compounds typically discussed in these circles). While it probably possesses some abuse potential it does not cause the reinforcing effects and dangerous parasomnias/automatisms that drugs like benzodiazepines and zolpidem do. In my opinion this makes it far safer than those drugs.

(Note: Many of you may be interested in the drug precisely for its hallucinogenic effects. Those of you should know it takes ~30–40mg to induce benign hallucinogenic/dissociative effects, compared to the 10–20mg therapeutic doses for sleep. It is said to be not similar in character to benzos/Z-drugs, and is difficult to compare to anything else besides the related muscimol)

Hamilton Morris even said a scientist at Merck reached out to him to say that the employees there were equally mystified as to why development was discontinued given how well it was doing in trials. Morris speculates it was likely scrapped due to heightened regulatory panic surrounding Ambien-induced parasomnias at the time—an ironically stupid decision, given gaboxadol explicitly does not cause these effects, but I guess they were worried about the hallucinations.

Despite it being unpatented, totally legal as a research chemical, and clinically confirmed by pharma to be safe and effective, it remains nearly impossible to source affordably. Legitimate institutional vendors (e.g., Sigma-Aldrich) sell it for hundreds of dollars per 100mg, and you typically have to be a legitimate business to purchase.

We often see compounds in this space with auspicious mechanisms but zero clinical safety data, or completely safe supplements that do absolutely nothing. Gaboxadol is the rare exception: a drug with a fully elucidated mechanism, proven efficacy in large human RCTs, and profound superiority over our current options. In some ways it may even represent that holy grail of a drug that gets you high but does not get you addicted, is well-studied, safe, and even has legitimate therapeutic use. I just wish I could finally get my paws on it!

I’m a relatively severe lifelong insomniac. Over the last year or so I’ve been studying sleep physiology and pharmacology, and I recently learned about gaboxadol. From Hamilton Morris’s writings about it to reading the actual studies, I’ve become very interested in it for its medicinal use as a hypnotic to improve sleep quality (namely sleep onset latency) and architecture. Unlike Z-drugs and benzodiazepines, it does not suppress deep sleep or dependence. It actually robustly enhances N3 sleep, but unlike say phenibut, gabapentin, etc. does not seem to cause addiction/tolerance, preserves REM and overall produces a much more physiologically natural sleep architecture, and does not have the harmful neurological effects of α2δ calcium channel inhibition. In fact, it really has very few downsides to speak of compared to other hypnotics or CNS depressants, with the exception of orexin antagonists, and has uniquely beneficial effects on sleep architecture. This might be due to its selectivity for δ-subunit containing GABA_A receptors, which are highly expressed in the arousal/wakefulness-promoting regions in the thalamus, or due to its tonic GABA_A inhibition rather than the phasic inhibition of other drugs. It might also be because the α4β3δ receptors for which gaboxadol has the highest selectivity and activity are positively modulated by histamine, so agonizing them might cause a homeostatic braking effect on the histaminergic tuberomamillary nucleus, but that's just a hypothesis I invented.

I think orexin receptor antagonists (both DORAs like daridorexant, lemborexant, etc.) and 2-SORAs (seltorexant) are excellent drugs with broad applicability and terrific therapeutic indexes, but I wish they were powerful enough for severe insomnia like I have. Instead I have to partially rely on drugs like trazodone, zaleplon, and zolpidem which create concerns for long-term use. And while ORAs were an improvement over Z-drugs by not significantly suppressing slow wave sleep (Z-drugs do so slightly, but less than benzodiazepines), they are known more for increasing REM. Again, while this does not come at the expense of SWS, it is not optimal either. N3/SWS sleep is most implicated in brain function and cognitive health, via mechanisms like glymphatic system activity, memory consolidation, synaptic pruning, metabolic restoration, well as other physical health benefits like exercise recovery, insulin sensitivity, etc. You can actually completely kill your REM sleep with an MAOI and be more or less fine, but lack of deep sleep is terrible. True that gaboxadol is not the only drug that increases delta and theta band power; other agents include GHB, phenibut, gabapentin, and pregabalin, but these all have profound downsides which gaboxadol apparently does not. Ultimately, I think gaboxadol is unmatched in its ability to promote restorative sleep.

Is pretty well studied in humans (at least by the standards of the stuff we usually talk about in these circles…), and while it definitely has some recreational/abuse potential, it seems people are taking around 80mg+ to get mild hallucinogenic effects compared to 10–15mg for sleep. I really recommend reading Hamilton Morris’s article, or even just the Wikipedia article. He even said that after publishing it, more chemists and employees from Merck reached out to him to express confusion as to why they abandoned phase III trials given how well it was doing. Development of gaboxadol for insomnia was cancelled during a time when there was heightened fear among regulators (and pharmaceutical executives, apparently) of parasomnias caused by Ambien, but gaboxadol does not cause these. Not only is it a superior to zolpidem as a hypnotic, but it also seems to have less abuse potential. And zolpidem's is already pretty low in my opinion...

I have not been able to find it on the grey market for a remotely reasonable price. There are research chemical suppliers (i.e. actual research chemical vendors like Sigma-Aldrich who sell only to legitimate institutions and registered businesses, conduct customer audits, do not ship to residential addresses, etc.) selling it for about $200 per 100mg (about ten doses worth). It is completely legal as a research chemical and unpatented, although the synthesis might be a little tedious.

Often in this space there are compounds that sound interesting but are stymied by safety problems. Sometimes, compounds seem promising but lack safety data to provide necessary peace of mind. Some compounds may have an auspicious-sounding mechanism, but lack research to actually confirm that they work as expected or are even effective. And then of course there are completely safe supplements that do absolutely nothing. And, if you know where to look, you can usually find someone willing to sell you any of these questionable substances with even more questionable authenticity and purity. Gaboxadol is a drug with a well understood mechanism, confirmed safety and efficacy in large-scale human RCTs, and extremely promising benefits superior to most current options—but I still can't get my paws on it!